by Brandon Tudor | Mar 12, 2025 | Uncategorized
Efruxifermin reverses MASH-related cirrhosis in Phase 2 trial, per a recent press release from Akero Therapeutics. Treatment with Akero Therapeutics’ investigational efruxifermin led to reversals of compensated cirrhosis, or irreversible scarring in a...
by Brandon Tudor | Mar 8, 2025 | Uncategorized
From McMaster University: “As the most common liver disease in the world, Hepatitis B is a life-threatening liver infection caused by the hepatitis B virus, or HBV. It can cause chronic infection and put people at a high risk of death from cirrhosis (scarring of...
by Brandon Tudor | Mar 5, 2025 | Uncategorized
Great video from the Liver Education Advocates event (featuring Gina Madison) in Pittsburgh on March 2, 2025, where folks received a liver scan via the Mindray Hepatus 6. SOURCE: WTAE Hepatus 6 Summary:A new era for noninvasive diagnosis of liver disease with a wide...
by Brandon Tudor | Mar 4, 2025 | Uncategorized
In the 02/25/25 article “MASH Drives Increasing Global Incidence of Cirrhosis, Chronic Liver Diseases” in HCP Live, the conclusion is that focused efforts targeted at the metabolic risk factors to curb the rising incidence of MASH, increasing linkage to...
by Brandon Tudor | Mar 2, 2025 | Uncategorized
From the AJMC Journal 02/27/2025: “At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline.” Per the article by Rose...
